Monthly Archives: March 2015

Canaccord Genuity Maintains a Hold Rating on Teva Pharma

In a report released yesterday, Corey Davis from Canaccord Genuity maintained a Hold rating on Teva Pharma (NYSE: TEVA), with a price target of $63. The company’s shares opened today at $62.30, close to its 52-week high of $64.08. Teva

Ritchie Bros. Receives a Sell from Canaccord Genuity

Canaccord Genuity analyst Yuri Lynk reiterated a Sell rating on Ritchie Bros. (NYSE: RBA) today and set a price target of $23. The company’s shares opened today at $24.94. Lynk observed, “We reiterate our SELL rating and US$23.00 one-year target

MLV & Co. Believes RARE Won’t Stop Here

MLV & Co. analyst Arlinda Lee initiated coverage with a Buy rating on Ultragenyx (NASDAQ: RARE) yesterday and set a price target of $79. The company’s shares opened today at $62.09, close to its 52-week high of $64.99. Lee noted,

Magna International Receives a Buy from Canaccord Genuity

Canaccord Genuity analyst David Tyerman reiterated a Buy rating on Magna International (NYSE: MGA) yesterday. The company’s shares opened today at $53.66. Tyerman wrote, “We continue to recommend investors BUY Magna (MGA) shares as our good outlook for the company

Lion Biotechnologies Receives an Overweight from Piper Jaffray

Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Lion Biotechnologies (OTHEROTC: LBIO) yesterday and set a price target of $21. The company’s shares opened today at $12.11. Schimmer said, “LBIO reported positive data from a TIL and Y

Illumina Receives a Buy from BTIG

In a report released today, Dane Leone from BTIG maintained a Buy rating on Illumina (NASDAQ: ILMN), with a price target of $240. The company’s shares opened today at $185.64. Leone observed, “Today Illumina and Berry Genomics announced that the